Obesity Treatment Market Size & Forecast, By Drugs (Combination Drugs, Appetite Suppressants, Malabsorption & Satiety Drugs), By Surgery & Devices (Adjustable Gastric Banding, Roux-en-Y Gastric Bypass, Sleeve Gastrectomy, Biliopancreatic Diversion With Duodenal Switch, Endoscopic Procedures) And Trend Analysis To 2024

Published: Sep, 2015 | Pages: 92 | Publisher: Grand View Research
Industry: Medical Devices | Report Format: Electronic (PDF)

The global obesity treatment market is expected to reach USD 15.6 billion by 2024, according to a new report by Grand View Research, Inc. Upward trend in sedentary lifestyles, physical inactivity, and unhealthy food habits are the vital factors responsible for the high prevalence of obesity. According to the Institute of Health Metrics and Evaluation, about 30.0% of the global population is either obese or overweight.

Additionally, along with commercial availability of solutions for weight management, technological advancements introduced by the vertical players and supportive initiatives undertaken by the governments, create more awareness with regard to obesity and its impact on health. This is further driving the growth of the obesity treatment market.

There are various approaches for weight management such as diet, exercise, drugs, minimally invasive devices & implants, and surgeries. Amongst the prevalent drugs, the combination drugs hold the largest market share whereas satiety drugs that provide a feeling of fullness appear as the fastest growing segment in the obesity treatment market.

In surgeries, gastric bypass procedures form the largest growing segment whereas the minimally invasive endoscopic procedure segment that involves surgical placement of implants and devices, such as satiety devices and gastric empting devices, is the fastest growing space.

Intense competition in the private sector has driven advancements and innovation toward the development of the latest techniques for obesity treatment that are offered in private hospitals and clinics. As a result, the demand for minimally invasive procedures is swiftly increasing. In addition, increasing awareness of obesity & the associated diseases and the commercial availability of weight management solutions is propelling the obesity treatment market.

Further key findings from the study suggest:

The combination drugs segment for obesity captured the largest market share of around 53% of the global market in 2015. The largest share of the segment was mainly attributed to the rising prevalence of obesity and the synergistic effect of combination therapy in weight management.

In the surgeries and devices segment, gastric bypass is the largest growing with a market share of over 32%, while the minimally invasive endoscopic procedures segment is anticipated to be the fastest growing category in obesity treatment for the forecast period

North America accounts for the largest market share of around 52.0% in 2015. This region is expected to maintain its dominance throughout the forecast period due to the heavy R&D investments deployed to develop effective weight management solutions and the commercial availability of minimally invasive procedures.

Asia Pacific is anticipated to witness the fastest growth during the forecast period. Growing awareness of adverse health effects related to excess weight and its impact amongst individuals, rising disposable income, improving healthcare infrastructure, and the emerging medical tourism industry are some of the factors expected to drive the growth of the Asia Pacific sector during the forecast period.

Some key market participants include VIVUS, Inc., Arena Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, Allergan Plc, Medtronic, Ethicon (subsidiary of Johnson & Johnson), Cousin Biotech, EnteroMedics, Inc., and USGI Medical, Inc.

The players are focusing on product innovation through extensive R&D activities and introducing new combination drugs & satiety products. In addition, the sector giants are developing minimally invasive procedures and initiating collaborations to expand their geographical territories to gain greater market presence.

 Table of Contents


Chapter 1 Research Methodology
                   1.1 Information Procurement
                   1.2 Data Analysis
Chapter 2 Executive Summary
Chapter 3 Market Snapshot
Chapter 4 Market Variables, Trends & Scope
                   4.1 Market Segmentation & Scope
                      4.1.1 Market Driver Analysis
                            4.1.1.1. Growing global prevalence of obesity
                            4.1.1.2. Changing lifestyles and food habits
                            4.1.1.3. Demand for minimally invasive procedures
                            4.1.1.4. Rising awareness about the different bariatric surgeries
                      4.1.2 Market Restraint Analysis
                            4.1.2.1.Complexities related to obesity treatment
                            4.1.2.2.High cost associated to surgeries
                            4.1.2.3. Limited insurance coverage
                   4.2 Obesity Treatment Market - SWOT Analysis
                   4.3 Industry Analysis - Porter's
Chapter 5 Market Categorization 1: Product Estimates & Trend Analysis
                   5.1.Obesity Treatment Market: Product Movement Analysis
                      5.1.1. Combination drugs
                      5.1.2. Appetite supressants
                      5.1.3. Malabsorption
                      5.1.4. Satiety
Chapter 6 Market Categorization 2: Surgery & Devices Estimates & Trend Analysis
                   6.1. Obesity Treatment Market: Surgery & Devices Movement Analysis
                      6.1.1. Adjustable gastric banding
                      6.1.2. Roux-en-Y gastric bypass
                      6.1.3. Sleeve gastrectomy
                      6.1.4. Billiopancreatic diversion with duodenal switch
                      6.1.5. Endoscopic procedures
                      6.1.6. Others
Chapter 7 Market Categorization 2: Regional Estimates & Trend Analysis, by Product
                   7.1. North America
                      7.1.1. U.S.
                      7.1.2.Canada
                   7.2. Europe
                      7.2.1UK
                      7.2.2. Germany
                      7.2.3 Asia Pacific
                            7.2.3.1 Japan
                            7.2.3.2 China
                      7.2.4 Latin America
                            7.2.4.1 Brazil
                            7.2.4.2 Mexico
                      7.2.5 MEA
                            7.2.5.1 South Africa
Chapter 8 Competitive Landscape
                   8.1 Strategy framework
                   8.2 Market participation categorization
                   8.3 Company Profiles
                      8.3.1 VIVUS, Inc.
                            8.3.1.1 Company overview
                            8.3.1.2 Financial performance
                            8.3.1.3 Product benchmarking
                            8.3.1.4 Strategic initiatives
                      8.3.2 Arena Pharmaceuticals, Inc.
                            8.3.2.1 Company overview
                            8.3.2.2 Financial performance
                            8.3.2.3 Product benchmarking
                            8.3.2.4 Strategic initiatives
                      8.3.3 F. Hoffmann-La Roche, Ltd.
                            8.3.3.1 Company overview
                            8.3.3.2 Financial performance
                            8.3.3.3 Product benchmarking
                            8.3.3.4 Strategic initiatives
                      8.3.4 Novo Nordisk A/S
                            8.3.4.1 Company overview
                            8.3.4.2 Financial performance
                            8.3.4.3 Product benchmarking
                            8.3.4.4 Strategic initiatives
                      8.3.5 Orexigen Therapeutics, Inc.
                            8.3.5.1 Company overview
                            8.3.5.2 Financial performance
                            8.3.5.3 Product benchmarking
                            8.3.5.4 Strategic initiatives
                      8.3.6 Allergan
                            8.3.6.1 Company overview
                            8.3.6.2 Financial performance
                            8.3.6.3 Product benchmarking
                            8.3.6.4 Strategic initiatives
                      8.3.7 Cousin Biotech
                            8.3.7.1 Company overview
                            8.3.7.2 Financial performance
                            8.3.7.3 Product benchmarking
                            8.3.7.4 Strategic initiatives
                      8.3.8 EnteroMedics, Inc.
                            8.3.8.1 Company overview
                            8.3.8.2 Financial performance
                            8.3.8.3 Product benchmarking
                            8.3.8.4 Strategic initiatives
                      8.3.9 Ethicon ( Subsidiary of Johnson & Johnson)
                            8.3.9.1 Company overview
                            8.3.9.2 Financial performance
                            8.3.9.3 Product benchmarking
                            8.3.9.4 Strategic initiatives
                      8.3.10 Medtronic
                            8.3.10.1 Company overview
                            8.3.10.2 Financial performance
                            8.3.10.3 Product benchmarking
                            8.3.10.4 Strategic initiatives
                      8.3.11 USGI Medical, Inc.
                            8.3.11.1 Company overview
                            8.3.11.2 Financial performance
                            8.3.11.3 Product benchmarking
                            8.3.11.4 Strategic initiatives
                      8.3.12 Mediflex Surgical Products
                            8.3.12.1 Company overview
                            8.3.12.2 Financial performance
                            8.3.12.3 Product benchmarking
                            8.3.12.4 Strategic initiatives

List of Tables


TABLE 1 Anti-Obesity Products and cost per month
TABLE 2 North America obesity treatment market, 2014 - 2024 (USD Million)
TABLE 3 North America obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 4 North America obesity treatment market, by surgery, & devices 2014 - 2024 (USD Million)
TABLE 5 U.S. obesity treatment market, 2014 - 2024 (USD Million)
TABLE 6 U.S. obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 7 U.S. obesity treatment market, by surgery & devices 2014 - 2024 (USD Million)
TABLE 8 Canada obesity treatment market, 2014 - 2024 (USD Million)
TABLE 9 Canada obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 10 Canada obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 11 Europe obesity treatment market, 2014 - 2024 (USD Million)
TABLE 12 Europe obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 13 Europe obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 14 UK obesity treatment market, 2014 - 2024 (USD Million)
TABLE 15 UK obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 16 UK obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 17 Germany obesity treatment market, 2014 - 2024 (USD Million)
TABLE 18 Germany obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 19 Germany obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 20 Asia Pacific obesity treatment market, 2014 - 2024 (USD Million)
TABLE 21 Asia Pacific obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 22 Asia Pacific obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 23 Japan obesity treatment market, 2014 - 2024 (USD Million)
TABLE 24 Japan obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 25 Japan obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 26 China obesity treatment market, 2014 - 2024 (USD Million)
TABLE 27 China obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 28 China obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 29 Latin America obesity treatment market, 2014 - 2024 (USD Million)
TABLE 30 Latin America obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 31 Latin America obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 32 Brazil obesity treatment market, 2014 - 2024 (USD Million)
TABLE 33 Brazil obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 34 Brazil obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 35 Mexico obesity treatment market, 2014 - 2024 (USD Million)
TABLE 36 Mexico obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 37 Mexico obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 38 MEA obesity treatment market, 2014 - 2024 (USD Million)
TABLE 39 MEA obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 40 MEA obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)
TABLE 41 South Africa obesity treatment market, 2014 - 2024 (USD Million)
TABLE 42 South Africa obesity treatment market, by drugs, 2014 - 2024 (USD Million)
TABLE 43 South Africa obesity treatment market, by surgery & devices, 2014 - 2024 (USD Million)